Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:

In8Bio Inc (INAB)

In8Bio Inc (INAB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
IN8bio Announces Promising Phase 1 Trial Results for INB-200 in Glioblastoma Patients, Highlighting Enhanced Survival and Immune Response Quiver Quantitative, Inc. - Mon Nov 25, 4:16PM CST

INB-200 trial shows promising survival and immune response in glioblastoma patients, highlighting potential as innovative therapy.Quiver AI SummaryIN8bio, Inc. has reported promising results from its Phase...

INAB : 0.3038 (-4.35%)
IN8bio Reports Continued Durable Remissions in Phase 1 Trial of INB-200 in Plenary Oral Presentation at the Society for Neuro-Oncology (SNO) Annual Meeting GlobeNewswire - Mon Nov 25, 6:00AM CST

INAB : 0.3038 (-4.35%)
IN8bio Reports Third Quarter 2024 Financial Results and Recent Corporate Highlights GlobeNewswire - Tue Nov 12, 3:26PM CST

INAB : 0.3038 (-4.35%)
IN8bio Announces Plenary Oral Presentation at the 2024 Society for Neuro-Oncology (SNO) Annual Meeting GlobeNewswire - Tue Nov 12, 6:00AM CST

INAB : 0.3038 (-4.35%)
IN8bio Announces Upcoming Presentation at the 2024 American Society of Hematology (ASH) Annual Meeting GlobeNewswire - Tue Nov 5, 8:00AM CST

INAB : 0.3038 (-4.35%)
Big Developments in Cancer Treatments set for Upcoming ASCO 2023 Annual Meeting in June PR Newswire - Wed May 31, 2023

/PRNewswire/ -- USA News Group - With this year's Annual Meeting of the American Society of Clinical Oncology (ASCO 2023) less than 30 days away, there's...

ONC.TO : 1.31 (-1.50%)
ONCY : 0.9350 (-2.00%)
JAZZ : 124.34 (-1.84%)
GERN : 4.10 (+0.74%)
INAB : 0.3038 (-4.35%)
VCYT : 41.10 (+3.81%)
Big Developments in Cancer Treatments set for Upcoming ASCO 2023 Annual Meeting in June FinancialNewsMedia - Wed May 31, 2023

EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:JAZZ),(NASDAQ:GERN),(NASDAQ:INAB),(NASDAQ:VCYT) EQNX::TICKER_END

ONCY : 0.9350 (-2.00%)
ONC.TO : 1.31 (-1.50%)
JAZZ : 124.34 (-1.84%)
GERN : 4.10 (+0.74%)
INAB : 0.3038 (-4.35%)
VCYT : 41.10 (+3.81%)
Significant Oncology Results Set to be Delivered as Oral Presentations at ASCO 2023 BayStreet.ca - Wed May 31, 2023

USA News Group – With this year’s Annual Meeting of the American Society of Clinical Oncology (ASCO 2023) less than 30 days away, there’s plenty of anticipation for updates on some of the biggest...

ONCY : 0.9350 (-2.00%)
ONC.TO : 1.31 (-1.50%)
JAZZ : 124.34 (-1.84%)
GERN : 4.10 (+0.74%)
INAB : 0.3038 (-4.35%)
VCYT : 41.10 (+3.81%)
IN8bio Observes Durable Morphologic Complete Responses in Ongoing Phase 1 Clinical Trial of INB-100, an Allogeneic Gamma-Delta T Cell Therapy in High-Risk Leukemia Patients Globe Newswire - Wed Jul 27, 2022

All three patients from the first cohort of high-risk relapsed acute-myeloid leukemia (AML) patients dosed to-date with INB-100 remain alive and...

INAB : 0.3038 (-4.35%)
Newly Issued European Patent Broadens IN8bio’s Drug Resistant Immunotherapy (DRI) Platform Globe Newswire - Thu Jul 21, 2022

European patent covers any genetic modification conveying chemotherapy resistance to immune cell types, including gamma-delta T cells and now natural...

INAB : 0.3038 (-4.35%)

Barchart Exclusives

3 Dividend Stocks to Buy Now With Yields of About 4% or More Barchart - 1 hour ago
Three dividend stocks, Kimco Realty, Perrigo Company, and Permian Resources, are highlighted as attractive options for investors seeking steady income, with yields of 3.9% or more and strong fundamentals across the real estate, healthcare, and energy sectors. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar

[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot